Dr. Bart van de Sluis graduated in Biology from the Utrecht University, the Netherlands. In 1998, he was appointed as a PhD student at the Department of Human Genetics at the Utrecht University, the Netherlands, under the supervision of Prof. dr. Cisca Wijmenga. He received his PhD degree (cum laude, highest distinction in the Netherlands) in 2002 on the basis of the identification of a copper toxicosis gene (COMMD1, previous known as MURR1) in Bedlington terriers. As a post-doctoral fellow, he continued his scientific career in the lab of Dr. Paul Liu at the Genetics and Molecular Biology Branch at the National Human Genome Research Institute (NIH, Bethesda, USA). He worked on a project to identify novel players in leukemogenesis and hematopoiesis. Mid-2004, he returned back to Utrecht as a post-doc on a joined project of dr. L. Klomp and Prof. dr. C. Wijmenga. He characterized a Commd1 knockout mouse, which he generated in the lab of Dr. Paul Liu at NIH. In March 2008, he moved to Groningen to set up his own research group to further understand the molecular regulation of lipid metabolism, and how inflammation is kept under control, with the focus on the NF-kB signaling pathway. He is using cellular and mouse models to study these different processes in great detail. In addition, he runs a mouse transgenic mouse facility at the RUG/UMCG to generate new mouse models using different approaches, such as the CRISPR/Cas9 methodology. In the recent years, he is awarded with several grants, including a Dutch NWO-ALW grant, H2020-MSCA-ITN-2020 grant (EndoConnect) and participates as a PI/work package leader in Dutch and European consortia.